Abilify Related Published Studies
Well-designed clinical trials related to Abilify (Aripiprazole)
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a
randomized, double-blind, active parallel-controlled, multicenter clinical trial. [2014]
A head-to-head comparison of aripiprazole and risperidone for safety and treating
autistic disorders, a randomized double blind clinical trial. [2014]
Systematic review of clinical trials of aripiprazole for treating attention
deficit hyperactivity disorder. [2013]
A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole
in children and adolescents with Tourette's disorder. [2013]
Early antipsychotic response to aripiprazole in adolescents with schizophrenia:
predictive value for clinical outcomes. [2013]
The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire
in treatment resistant depression. [2013]
Long-term safety and tolerability of aripiprazole once-monthly in maintenance
treatment of patients with schizophrenia. [2013]
Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical
study from India. [2013]
Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. [2011.12.02]
Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. [2011.11]
Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. [2011.10]
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. [2011.09.20]
Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. [2011.09]
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). [2011.09]
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. [2011.09]
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. [2011.06]
Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. [2011.06]
Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. [2011.05]
An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. [2011.05]
Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. [2011.04]
Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. [2011.04]
Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. [2011.04]
Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. [2011.03]
Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. [2011.02.01]
Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study. [2011.02]
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. [2011.01.15]
Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. [2011]
Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh
major depressive disorder: a randomized, double-blind, controlled study. [2011]
Aripiprazole in the maintenance treatment of bipolar disorder: a critical review
of the evidence and its dissemination into the scientific literature. [2011]
Aripiprazole as adjunctive therapy for patients with major depressive disorder:
overview and implications of clinical trial data. [2011]
Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. [2011]
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. [2010.12]
The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model. [2010.11]
A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). [2010.11]
Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. [2010.10]
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. [2010.09]
Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. [2010.09]
Long-term treatment with aripiprazole on the waking and postprandial urges to smoke in Chinese heavy smokers. [2010.08]
The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. [2010.08]
Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. [2010.07]
[A control study of aripiprazole and tiapride treatment for tic disorders in children] [2010.06]
A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. [2010.06]
Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. [2010.05.04]
Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. [2010.03]
Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data. [2010.02]
Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. [2010.01]
Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. [2010]
Aripiprazole for the maintenance treatment of bipolar I disorder: A review. [2010]
Long-term treatment with aripiprazole on the waking and postprandial urges to
smoke in Chinese heavy smokers. [2010]
Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in
the maintenance treatment of bipolar I disorder: a post hoc analysis of a
randomized, double-blind, placebo-controlled trial. [2010]
A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report
assessment of improvement in core depressive symptoms with adjunctive
aripiprazole. [2010]
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive
therapy: studies in healthy subjects and in patients with major depressive
disorder. [2010]
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. [2009.12]
A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. [2009.11]
Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. [2009.10]
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. [2009.10]
Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. [2009.10]
Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. [2009.09]
Focus on Aripiprazole: A Review of its use in Child and Adolescent Psychiatry. [2009.08]
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. [2009.08]
A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. [2009.08]
A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. [2009.07]
UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). [2009.06]
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. [2009.05.15]
Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. [2009.05]
Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. [2009.05]
Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers. [2009.04.01]
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. [2009.04]
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. [2009.04]
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. [2009.04]
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. [2009.03.15]
Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. [2009.03]
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. [2009.02]
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. [2009.02]
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. [2009.02]
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. [2009.01]
A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. [2009.01]
Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. [2009.01]
An Open-Label Assessment of Aripiprazole in the Treatment of PTSD. [2009]
Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). [2009]
Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. [2009]
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). [2008.12.22]
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. [2008.12]
Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. [2008.12]
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. [2008.12]
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. [2008.12]
Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. [2008.12]
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. [2008.11]
Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. [2008.11]
Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. [2008.10]
Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. [2008.08]
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. [2008.07]
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. [2008.05]
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. [2008.05]
Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. [2008.05]
Effects of aripiprazole on subjective and physiological responses to alcohol. [2008.04]
Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. [2008.04]
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. [2008.03.26]
Aripiprazole Augmentation in Clozapine-Treated Patients With Refractory Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. [2008.03.18]
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. [2007.12]
Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. [2007.10]
|